The manufacturer of Conjugated Estrogens / Norgestrel (Prempak-C)® has written to clinicians to inform them of stock shortages.
The letter from the Medical Director states that there is a short-term production difficulty that is affecting supplies. They are working urgently to resolve the manufacturing difficulties and they provide a website address for weekly updates.
Prempak-C is licensed for hormone replacement therapy (HRT) in oestrogen deficiency and for prevention of osteoporosis in high-risk women who cannot take alternative products. The findings of the Women's Health Initiative have restricted the place of HRT products since many expected benefits of HRT were not demonstrated in real life studies while many of the harms remain.
Action: The shortage of Prempak-C is an opportunity to review the need for treatment. Prescribing should be stopped where the risks now outweigh the benefits of treatment.